Hellsgate Vectors Simplifies the Use of HairpinRNAi
News Sep 16, 2005
CSIRO has announced that one of its innovations for determining gene function has been granted a US patent clarifying its position in the international gene silencing arena.
Hellsgate, named after one of its developers Dr Chris Helliwell, is a set of RNAi vectors that allow researchers to knock out the expression of hundreds to thousands of selected genes.
“RNAi vectors are very hard to make, but with Hellsgate, which uses Gateway™ technology, you can make either one or up to 100 hairpins constructs from start to finish in just two days,” says CSIRO Plant Industry Business Development Manager Dr Bill Taylor.
The molecular tool is just one of a family of CSIRO-developed vectors designed to simplify the use of hairpinRNAi – CSIRO’s gene silencing technology – in functional genomics and trait development and the first to be granted a US patent.
“We’re seeing a lot of interest in Hellsgate and its vector-siblings, Stargate and Watergate, by the plant research community in particular with 2,000 distributed to research labs around the world,” says Dr Taylor.
“A major focus for many of these researchers is the discovery of genes responsible for key traits, such as resistance to pests and diseases or the ability to grow in hostile environments.”
“Hellsgate is the technology of choice to confirm gene function so that breeding of new varieties can be based on genes with proven function.”
Dr Taylor says the effectiveness of the CSIRO invention is highlighted by the use of a Hellsgate vector by the Arabidopsis Genomic RNAi Knock-Out Line Analysis (AGRIKOLA) consortium.
The European research consortium is using the vectors to create a library of constructs for every gene in Arabidopsis.
The technology works through a natural surveillance system that detects and destroys double stranded RNA in cells.
The Hellsgate vectors deliver double stranded hairpin RNA molecules corresponding to each selected gene, thereby destroying the messenger RNA for that gene and preventing its expression, silencing the gene.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.